Back

Medscape, LLC

  • Cell Transplantation

Changing the Face of Allogeneic HCT With Novel Engineered Cellular Therapeutics

The goal of this activity is for learners to be better able to evaluate advancements in novel cellular therapies used for graft engineering to optimize clinical outcomes in allogeneic hematopoietic cell transplantation (alloHCT).

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits

MOC types

ABIM — Medical KnowledgeUp to 0.5 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 0.5 credits
  • MOC · Up to 0.5 points
  • Commercial Support
  • Released
    Oct 16, 2025
  • Last day to claim credit
    Oct 17, 2026 5 days left